Pieris Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Note 3 - Revenue (Details Textual)

Note 3 - Revenue (Details Textual) $ / shares in Units, $ in Thousands				1 Months Ended		3 Months Ended		6 Months Ended	12 Months Ended
	Apr. 24, 2021 USD ($)	Mar. 24, 2021 USD ($) $ / shares shares	Jan. 01, 2019 USD ($)	Sep. 30, 2023 USD ($)	Jan. 31, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2017	May 19, 2021 USD ($)	Feb. 08, 2018	May 02, 2017 USD ($)
Contract with Customer, Liability, Current									$ 0	$ 20,824
Increase in Contract With Customer Liability									0
Decrease in Contract with Customer, Liability									39,700
Amendment of the Second Seagen Amendment [Member]
Revenue from Contract with Customer, Excluding Assessed Tax				$ 10,100
Genentech [Member]
Number Of Initial Research Programs												2
Contract with Customer, Liability, Revenue Recognized						$ 12,500
Seattle Genetics Inc. [Member]
Amended Collaboration Agreement, Resale of Stock, Period (Day)		60 days
Seattle Genetics Inc. [Member] \| Private Placement [Member]
Contract with Customer, Liability, Total		$ 3,300
Sale of Stock, Number of Shares Issued in Transaction (in shares) \| shares		3,706,174
Sale of Stock, Consideration Received on Transaction		$ 13,000
Sale of Stock, Price Per Share (in dollars per share) \| $ / shares		$ 3.51
Sale of Stock, Fair Value, Price Per Share (in dollars per share) \| $ / shares		$ 2.61
Seattle Genetics Inc. [Member] \| License and Collaboration Agreement [Member]
Number of Research Programs		3											3
Seattle Genetics Inc. [Member] \| Other Arrangement [Member]
Number of Research Programs													2
Seattle Genetics Inc. [Member] \| Collaborative Arrangement [Member]
Revenue from Contract with Customer, Excluding Assessed Tax					$ 5,000	1,500				5,000
Astra Zeneca A B [Member]
Capitalized Contract Cost, Amortization									$ 300
Astra Zeneca A B [Member] \| Accounting Standards Update 2014-09 [Member]
Capitalized Contract Cost, Net, Total														$ 1,600
Capitalized Contract Cost, Gross			$ 1,100
Capitalized Contract Cost, Amortization			$ 300
Astra Zeneca A B [Member] \| License and Collaboration Agreement [Member]
Contract with Customer, Liability, Revenue Recognized								$ 4,000		$ 9,700
Contract with Customer, Liability, Current				$ 3,500				$ 3,500
Astra Zeneca A B [Member] \| License and Collaboration Agreement [Member] \| Maximum [Member]
Number of Collaboration Products														4
Astra Zeneca A B [Member] \| License and Collaboration Agreement [Member] \| Minimum [Member]
Number of Collaboration Products														2
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]
Contract with Customer, Liability, Revenue Recognized							$ 4,900
Number of Programs											4
Number of Novel Proteins											1
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| License and Collaboration Agreement [Member]
Contract with Customer, Liability, Current						$ 4,700
Number of Programs											5
License [Member] \| Genentech [Member]
Contract with Customer, Liability, Total												$ 20,000
License [Member] \| B P Assets X I I Inc [Member] \| Exclusive Product License Agreement [Member]
Contract with Customer, Liability, Total	$ 10,000
Revenue from Contract with Customer, Contribution Towards Manufacturing Activities	$ 4,000